<DOC>
	<DOCNO>NCT02547480</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacokinetic profile , safety , efficacy LifePearl microspheres loaded irinotecan treatment liver predominant mCRC chemoembolization .</brief_summary>
	<brief_title>LifePearl-Iri Pharmacokinetic Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patient least 18 year old Histologically proven mCRC At least 1 measurable liver metastasis &gt; 1 cm ( mRECIST ) Liver predominant disease ( ≥ 80 % metastatic disease confine liver ) No portal vein involvement Performance status 0 1 Life Expectancy ≥ 3m Adequate Hematologic function ( ANC≥1.5 10^9/l ; PLT≥75 10^9/l ; INR ( international normalize ratio ) ≤1.3 ) Adequate liver renal function ( Total bilirubin ≤2.0 mg/dl ; ALBUMINE 2.5g/dl ; Serum creatinine ≤2.0 mg/dl ; ALT ( alanine transaminase ) , AST ( aspartate transaminase ) ≤5 time ULN ) Less 50 % liver tumor replacement Patient provide write informed consent Patient affiliate social security equivalent system ( France ) Eligible curative treatment ( resection/RFA ) History hepaticocholangiojejunostomy obstructive biliary disease ( with/without previous treatment ) Previous liver embolization Contraindication intraarterial embolization local irinotecan administration Allergy contrast medium Patient cotreated potent CYP3A4/UGT1A1 ( cytochrome P450 3A4/uridine diphosphate glucuronosyltransferase 1A1 ) inducer , i.e . rifampin , rifabutin , phenytoin , phenobarbital , carbamazepine St John 's Wort Patient currently participate clinical trial investigational drug device study complete primary endpoint clinically interfere current study endpoint In Investigator 's opinion patient ( ) comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study Patient judicial protection ( France )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>liver</keyword>
	<keyword>metastatic</keyword>
</DOC>